Somatolactogens and diabetic retinopathy

Area of Science:

• Endocrinology
• Ophthalmology
• Diabetology

Background:

• Diabetic retinopathy (DR) is a significant complication of diabetes, projected to affect 16 million Americans by 2050.
• DR is a primary cause of blindness in working-age adults, characterized by retinal neovascularization and capillary non-perfusion.
• Somatolactogens, including pituitary growth hormone (GH-N), placental growth hormone (GH-V), and prolactin (PRL), are implicated in DR pathogenesis.

Purpose of the Study:

• To investigate the role of somatolactogens in the development and progression of diabetic retinopathy.
• To elucidate the mechanisms by which somatolactogens influence retinal neovascularization in DR.
• To explore the potential of targeting somatolactogen pathways for novel DR therapeutics.

Main Methods:

• Review of existing literature on somatolactogen expression and function in the retina.
• Analysis of studies linking GH-N, GH-V, and PRL levels to DR severity and neovascularization.
• Examination of the neuroprotective and pro-angiogenic roles of somatolactogens in ocular tissues.

Main Results:

• GH-N and PRL have been detected in the retina, exhibiting neuroprotective and pro-angiogenic properties.
• Elevated serum levels of GH-N, GH-V, and PL are associated with the promotion of DR.
• GH-N and PRL enhance neovascularization in DR, although some PRL isoforms display anti-angiogenic activity.

Conclusions:

• Somatolactogens play a crucial role in regulating ocular neuroprotection and angiogenesis.
• Understanding the precise mechanisms of somatolactogen-mediated angiogenesis is key to developing new treatments for DR.
• Targeting somatolactogen pathways offers a promising avenue for future DR drug development.